DEAD/H-box helicase 11 like 17 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored DDX11L17 profile across patient tissues and cancer cell-line models. DDX11L17 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, DDX11L17 is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, DDX11L17 RNA expression shows 8,137 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight READ, LIHC, and TGCT as cancer lineages where DDX11L17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DDX11L17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DDX11L17 survival associations across molecular data types. DDX11L17 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DDX11L17 RNA expression–survival associations across cancer types. High DDX11L17 expression shows unfavorable associations in READ, HNSC, CESC and KIRC, but favorable associations in MESO and BLCA. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for DDX11L17 RNA expression.
This table summarizes DDX11L17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for DDX11L17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DDX11L17 shows lower tumor expression in KICH and KIRC and higher tumor expression in LIHC, LUSC and HNSC. The LIHC box plot shows higher DDX11L17 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .002).
This table shows molecular features associated with DDX11L17 in patient tissues and cancer cell lines. In patient samples, DDX11L17 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
